GENDER DIFFERENCES IN DELAYS IN INITIATING DIFFERENCES IN DELAYS IN INITIATING DIFFERENCES IN DELAYS IN INITIATING SMEAR-POSITIVE PULMONARY TUBERCULOSIS PATIENTS IN NEPAL

Tara Singh Bam

A Dissertation Submitted in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy Program in Public Health
College of Public Health
Chulalongkorn University
Academic Year 2006
Copyright of Chulalongkorn University

Thesis Title	Gender Differences in Delays in Initiating Directly
	Observed Treatment among New Sputum
	Smear-Positive Pulmonary Tuberculosis Patients in
	Nepal
Ву	Tara Singh Bam
Field of Study	Public Health
Thesis Advisor	Robert S. Chapman, M.D., M.P.H.
Thesis Co-advisor	Professor Donald A. Enarson, M.D.
Accepted by the	ne College of Public Health, Chulalongkorn University, in
Partial Fulfillment of Ro	equirements for the Doctoral Degree.
	Dean of the College of Public Health rasak Taneepanichsakul, M.D.)
THESIS COMMITTEE	
Sathika	FguluChairperson
(Associate Pro	ofessor Sathirakorn Pongpanich, Ph.D.)
Rome	S. Chargeman. Thesis Advisor
(Robert S. Ch	apman, M.D., M.P.H.)
Duna	ldaa
(Professor Do	nald A. Enarson, M.D.)
Yu'y	an Prachmobowh Member
(Associate Pre	ofessor Vipan Prachuabmoh, Ph.D.)
<u> </u>	xur le Member
(Associate Pro	ofessor Narin Hiransuthikul, M.D., Ph.D.)

PH 041416 : MAJOR: PUBLIC HEALTH

KEY WORDS: GENDER, TUBERCULOSIS, DELAY, DOTS, NEPAL.

TARA SINGH BAM: GENDER DIFFERENCES IN DELAYS IN INITIATING DIRECTLY OBSERVED TREATMENT AMONG NEW SMEAR-POSITIVE PULMONARY TUBERCULOSIS PATIENTS IN NEPAL, THESIS ADVISOR: ROBERT S CHAPMAN, M.D., M.P.H., THESIS CO-ADVISOR: PROFFESOR DONALD A ENARSON, M.D., 233 pp

Background: Lengthened delays in diagnosis and treatment increase morbidity and mortality from tuberculosis (TB), risk of TB transmission, and risk of treatment failure. The aims of this study were: (1) to characterize and compare delays in initiating directly observed TB treatment, and (2) to investigate associations of gender and other factors with these delays, among new smear-positive pulmonary TB patients in Nepal.

Methods: The study was conducted in all three districts of the Kathmandu valley. Qualitative and quantitative methods were employed. Face to face interviews, using a standardized questionnaire, were conducted among 379 male and 237 female TB patients, who were enrolled at 37 randomly selected DOTS centres between January and August 2006. Delay intervals were calculated as patient delay (time interval from the onset of symptoms until the first visit to any type of provider), health system diagnosis delay (time interval from this first visit until date of diagnosis), and total delay (time interval from the onset of symptoms until start of treatment). Bivariate analysis, multivariable linear regression, and multilevel mixed models were employed in identifying the factors affecting delay intervals.

Results: The median total delay was 115 days for females and 95 days for males. Patient delay was significantly longer in females than in males (60 vs. 45 days, p<0.001). The health system diagnosis delay was also longer in females than males (34 vs. 29 days, p=0.013). A higher proportion (21.4%) of females than males (2.8%) entered the medical system by first accessing traditional healers. The mean frequency of visits to different health care providers, before start of treatment, was substantially higher in females than males (7.5 vs. 5.3). Self-recognition of symptoms as possible TB, and ability to decide by oneself to seek medical help, were strongly associated with shortened patient delay. Loss of income and perception of social isolation were associated with lengthened patient delay in females. In males, higher education and self-recognition of symptoms were associated with shortened patient delay. HIV-positive status, loss of income, and perception of coughing as not a serious matter were associated with lengthened patient delay. Consultation with traditional healers was associated with lengthened diagnosis delay. Visiting multiple providers, and not being advised to obtain a sputum test, were associated with lengthened diagnosis delay among females.

Conclusion: Gender inequalities in early access to DOTS should be remedied by increasing public awareness, promoting female autonomy in decision making, and developing effective cooperation between public and private sectors.

Field of study:Public Health	Student's signature . Fram
Academic year:2006	Advisor's signature Strat S. Changman
	Co-advisor's signature Qualdah

Acknowledgement

It is my great pleasure to extend my sincere gratitude and appreciation to Dr. Robert S. Chapman, my advisor, and Professor Donald A. Enarson, my co-advisor, from International Union Against Tuberculosis and Lung Disease, Paris, for their inspirations, encouragements, scientific guidance and supports throughout the study which enabled me to complete the study successfully in time.

I would like to acknowledge the valuable guidance of Associate Professor Sathirakorn Pongpanich, Associate Professor Vipan Prachuabmoh, Associate Professor Narin Hiransuthikul and Prof. Edgar Love. I also pay sincere thanks to Norwegian Association of Heart and Lung Patients (LHL), Norway for their financial support, particularly to Ms. Mette Koloumn, Ms. Silje Hagerup, and Olav Aalberg.

My long-standing association with the Nepal National Tuberculosis Control Programme has also been vital to the success of this thesis. I am especially grateful to Dr. D.S. Bam, Ministry of Health and Population, Dr. P. Malla, National Tuberculosis Centre, and Dr. K.K. Jha, SAARC Tuberculosis and HIV/AIDS Centre.

I would like to pay my sincere thanks to Sandeep Chitrakar, Geeta Acharya, Sandhya Dahal, Reshma K.C., Durga Pathak, Devi Gurung and Rabin Khatiwada for their support during the field study. Special thanks to my friends of Nepal Health Research Council Mr. Subod Karn and Mr. Nirvaya Sharma for their kind help.

Sincere thanks to my friends; Dr. Suresh Tiwari, Sita Ram Ghimire, Ramji Dhakal, Dr. Muni Raj Chhetri, and Krishna Basnet for their continuous collegial support. Many thanks also to my father-in-law, Mr. Ratan Bahadur Shah for his significant support to my study and my family. I gratefully acknowledge the great help of my brother-in-law Mr. Anand B. Chand and my nephew Ms. Sneha Chand. Thanks to Yingsak, Araya and Surada Suwannapak from CPH, for their computer and library help.

My heartfelt thank to my wife, Pramila Bam, for her remarkable supports to make my study completion a much easier and more pleasant way. Thanks to my mother, my children Tanu and Tanup, my brothers Tej and Suresh, who stood behind me and inspired me throughout the study period.

TABLE OF CONTENTS

	Page
ABSTRACT	iii
ACKNOWLEDGEMENT	iv
TABLE OF CONTENT	v
LIST OF TABLES	viii
LIST OF FIGURES	xi
ABBREVIATION	xii
CHAPTER I INTRODUCTION	1
1.1 Background	1
1.2 TB situation worldwide	1
1.3 TB situation in Nepal	3
1.4 TB control	3
1.5 Statement of the problem	4
1.6 Rationale	7
1.7 Research questions	14
1.8 Objectives	14
1.9 Research hypothesis	15
1.10 Operational definition	15
1.11 Conceptual framework	20
CHAPTER II LITERATURE REVIEW	22
2.1 Tuberculosis	22
2.2 Nepal country profile	24
2.3 Epidemiology of TB in Nepal	25
2.4 Delays in initiating TB treatment and its impact	29
2.5 Gender	33
2.6 A framework for the study of gender and TB	39
2.7 Why would women have a longer delay	40

TABLE OF CONTENTS (continued)

*	Page
CHAPTER III RESEARCH METHODOLOGY	68
3.1 Study setting	70
3.2 Research methodology	71
3.3 Study population	73
3.4 Sample population	73
3.5 Sample size	74
3.6 Inclusion and exclusion criteria	75
3.7 Sampling procedures	75
3.8 Data collection instruments	77
3.9 Validity and reliability	78
3.10 Data collection procedures	79
3.11 Measurements	81
3.12 Data analysis	82
3.13 Ethical consideration	85
3.14 Biases	86
3.15 Scope of the study	87
3.16 Budget support	87
3.17 Technical support	87
CHAPTER IV RESULTS	88
4.1 Quantitative study results	88
4.1.1 Patients' profile	89
4.1.2 Help seeking behavior	90
4.1.3 Socio-cultural characteristics	95
4.1.4 Summary characteristics related to accessibility	96
4.1.5 Clinical characteristics	96
4.1.6 Expenditure incurred prior to start of TB treatment	97
4.1.7 Health system related factors	99
4.1.8 Magnitude of delays	103

TABLE OF CONTENTS (continued)

	Page
4.1.9 Factors affecting patient delay	105
4.1.10 Multilevel analysis of patient delay	115
4.1.11 Factors affecting health system diagnosis delay	122
4.1.12 Multilevel analysis of health system diagnosis delay	132
4.1.13 Factors affecting total diagnosis delay, multilevel analysis	138
4.1.14 Factors affecting total delay, multilevel analysis	145
4.2 Qualitative study results	147
4.2.1 Gender differences in knowledge & perception	147
4.2.2 Gender differences by socio-cultural aspects	149
4.2.3 Gender differences in their role in the family	151
4.2.4 Gender differences in seeking care	152
4.2.5 Suggestions for improvements	158
CHAPTER V SUMMARY, DISCUSSION & RECOMMENDATION	162
5.1 Summary	162
5.2 Methodology consideration	166
5.3 Case detection	171
5.4 Help seeking behavior	172
5.5 Magnitude & determinants of patient delay	175
5.6 Magnitude & determinants of health system diagnosis delay	184
5.7 Magnitude and determinants of total diagnosis delay	189
5.8 Magnitude and determinants of total delay	192
5.9 Economic burden	194
5.10 Recommendations for policy implication	198
REFERENCES	200
APPENDIX	216
Appendix A	
CURRICULUM VITA	233

LIST OF TABLES

Tables		Page
1	Male:Female ratio of smear positive TB notification by age	23
2	Evolution of case finding in Nepal	27
3	Delays in health seeking of and tuberculosis diagnosis	33
4	Gender differences in delay from onset of symptoms	38
5	Population, estimated new smear positive cases	69
6	Symptoms at onset of TB and at any time prior to TB diagnosis	90
7	Recognition of symptoms, sources, and decision making	91
8	Reason for delay seeking medical help by gender	92
9	First treatment seeking and visit to providers at some time prior	93
10	Types of providers advising sputum test	94
11	Reason for delay not visiting DOTS centres	94
12	Source of influencing to visit DOTS centre for TB treatment	95
13	Patient tuberculosis cost data	98
14	Lost work days due to TB prior to TB diagnosis	99
15	Gender differences in delays	104
16	Patient delay by socio-demographic and economic	106
17	Patient delay by recognition of symptoms and decision	108
18	Patient delay by socio-cultural factors	109
19	Patient delay by knowledge	110
20	Patient delay by perception	111
21	Patient delay by access	112
22	Patient delay by behavioral factors	113
23	Patient delay by cost	113
24	Patient delay by clinical factors	114
25	Patient delay by help seeking	115
26a	Multilevel analysis for all cases	117
26b	Final multilevel analysis for all cases	117

LIST OF TABLES (continued)

Tables		Page
26c	Final multilevel analysis for all cases: regression coefficient	118
27a	Multilevel analysis for male cases only	119
27b	Final multilevel analysis for male cases only	119
27c	Final multilevel analysis for male cases: regression coefficient	120
28a	Multilevel analysis for female cases only	121
28b	Final multilevel analysis for female cases only	121
28c	Final multilevel analysis for female cases: regression coefficient	121
29	Health system diagnosis delay by venue	122
30	Health system diagnosis delay by demographic factors	123
31	Health system diagnosis delay by recognition of symptoms	124
32	Health system diagnosis delay by socio-cultural factors	125
33	Health system diagnosis delay by knowledge	126
34	Health system diagnosis delay by perception factors	127
35	Health system diagnosis delay by access factors	128
36	Health system diagnosis delay by behavioral factors	129
37	Health system diagnosis delay by cost	129
38	Health system diagnosis delay by help seeking	131
39a	Multilevel analysis for all cases	133
39b	Final multilevel analysis for all cases	133
39c	Final multilevel analysis for all cases: regression coefficient	134
40a	Multilevel analysis for male cases only	135
40b	Final multilevel analysis for male cases only	135
40c	Final multilevel analysis for male cases: regression coefficient	136
41a	Multilevel analysis for female cases only	137
41b	Final multilevel analysis for female cases only	138
41c	Final multilevel analysis for female cases: regression coefficient	138
42a	Total diagnosis delay: Multilevel analysis for all cases	140
42b	Total diagnosis delay: Final multilevel analysis for all cases	140

LIST OF TABLES (continued)

Fables		Page
42c	Total diagnosis delay: Final multilevel analysis for all cases: regression coefficient	141
43a	Total diagnosis delay: Multilevel analysis for male cases only	142
43b	Total diagnosis delay: Final multilevel analysis for male cases only	142
43c	Total diagnosis delay: Final multilevel analysis for male cases: regression coefficient	143
44a	Total diagnosis delay: Multilevel analysis for female cases only	144
44b	Total diagnosis delay: Final multilevel analysis for female cases	144
44c	Total diagnosis delay: Final multilevel analysis for female cases: regression coefficient	144
45a	Total delay: Multilevel analysis for all cases only	146
45b	Total delay: Final multilevel analysis for all cases	146
45c	Total delay: Final multilevel analysis for female cases: regression coefficient	147
46	Summary variables for which p≤0.10 in final multilevel	166

LIST OF FIGURES

Figure		Page
1	The pathway to TB care	12
2	Study pathway to TB care	13
3	Study conceptual framework	20
4	An ideal conceptual path of help seeking and barriers	21
5	Distribution of new smear positive by age and sex	28
6	Results of treatment, 1995-2003	29
7	Gender differentials for clarification and study at each step in the	
	course of effective TB control	39
8	Direct contextual influence on health care seeking behavior	66
9	Map shows top three districts with high burden of tuberculosis in	
	Nepal 2003/04	68
10	Sampling procedures for quantitative study	76
11	Time interval in days (median) along the pathway in accessing anti-	
	tuberculosis treatment with DOTS by gender	163

ABBREVIATION

TB Tuberculosis

DOTS Directly Observed Treatment Short-course

DOT Directly Observed Treatment

WHO World Health Organization

NTP National Tuberculosis Programme

HIV Human Immunodeficiency Virus

MoH Ministry of Health

IUATLD International Union Against Tuberculosis and Lung Disease

LHL Norwegian Association of Heart and Lung Patients

GoN Government of Nepal

NGO Non-governmental Organization

CBS Central Bureau of Statistics

NTC National Tuberculosis Centre

UNDP United Nation Development Programme

AFB Acid-fast bacilli

ARTI Annual Risk of TB Infection

FGD Focus Group Discussion

GLM General linear model